- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Gastrointestinal Pipeline Drugs
Credits: 1.0 contact hours (0.10 CEUs)
Michael Marlan Mohundro, PharmD, Director of Pharmacy, Our Lady of the Lake Regional Medical Center
Brice Labruzzo Mohundro, PharmD, Assistant Professor, University of Louisiana at Monroe College of Pharmacy—Baton Rouge Campus
Educational Objectives
After completing this activity, participants should be able to:
- Identify and compare mechanisms of action, safety, tolerability, and efficacy profiles of emerging therapies for common gastrointestinal (GI) disorders
- Recognize the roles of emerging therapies for the treatment of specific GI disorders
Target Audience: This activity is intended for pharmacists—in the community, health systems, or other environments—who treat patients with GI disorders, or any healthcare practitioners who are interested in the availability of new drugs to treat GI disorders.
Strategies Needed to Address Physical Activity Before, After CVD Events
August 1st 2025Black women had lower moderate-to-vigorous intensity physical activity scores when compared with Black and White men and their White female counterparts, highlighting the need for support across patient subgroups.
Read More
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
